Biotechnology company Immunic Therapeutics has completed a stock-for-stock exchange transaction with Vital Therapies.
Transaction is subject to competition authority approval and will mark Ding's third bolt-on in 2020
GP deploys capital from its third fund, which held a €150m final close in 2018 exceeding its target
Ross was previously deputy CIO and joined the company two years ago
Viv Adshead, former president and CEO of Ashfield Communications, agrees to join the IMC board